Skip to content

4512.T

WAKAMOTO PHARMACEUTICAL CO.,LTD.

スタンダード · 医薬品 · 医薬品 · JP

JPY 306.00
−0.97%
Ask drillr

Year over year

Reported trailing growth

Revenue
+16.8%
EBITDA
EBIT
+125.6%
EPS
+1.4%
Free cash flow
Operating cash flow

Forward estimates

Based on analyst estimates

Revenue
+7.6%
EBITDA
EPS
-32.9%

Three-year CAGR

Revenue
-2.4%
EBITDA
EBIT
Net income
-35.5%
EPS
-35.4%
Free cash flow

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026